H.C. Wainwright analyst Sean Lee raised the firm’s price target on Kazia Therapeutics (KZIA) to $13 from $2 and keeps a Buy rating on the shares following the adjusted ratio of U.S. shares to 500:1 from 100:1.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KZIA:
- Kazia Therapeutics Announces Promising Early Results in Breast Cancer Trial
- Kazia Therapeutics reports preliminary results from Phase 1b trial
- Kazia Therapeutics trading halted, volatility trading pause
- Kazia Therapeutics trading resumes
- Buy Rating for Kazia Therapeutics Driven by Promising Paxalisib Data and Strategic Developments